---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025626"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:14:44.083365+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences regains Nasdaq compliance and advances PRIME Phase 1b CKD study

## Summary
- Nasdaq confirmed REVB common stock meets minimum bid price and all continued listing requirements.
- Company cannot use 180-day grace period if bid price falls below $1.00 again; would receive delisting letter but may request hearing.
- PRIME Phase 1b study of Gemini IV in Stage 3-4 CKD patients has commenced, enrolling up to 40 patients across 5 cohorts.
- CEO James Rolke highlighted Nasdaq listing for liquidity, capital access, and talent retention.

## SEC filing metadata
- accession: 0000950170-25-025626
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/0000950170-25-025626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/revb-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025626
- JSON: https://secwatch.observer/filing/0000950170-25-025626.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025626.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.